口服维生素D预处理后蓝光光动力疗法显著改善面部光线性角化病:一项干预性队列对照试验
研究比较口服维生素D3预处理后蓝光光动力疗法与单纯光动力疗法对面部光线性角化病的疗效。结果显示维生素D3补充组病灶清除率显著高于对照组,且副作用无差异。结论认为口服维生素D3预处理可显著改善光动力疗法的临床反应,方案有前景且耐受良好。
要点
- 维生素D3补充组光线性角化病总体清除率为72.5%±13.6%,高于对照组的54.4%±22.8%。
- 维生素D缺乏患者(25-羟基维生素D3<31 ng/dL)面部病灶清除率为40.9%±42%,低于正常水平者的62.6%±14.2%。
- 两组副作用无差异,口服维生素D3预处理方案耐受良好。
核心结论
- 口服维生素D3预处理可显著改善光线性角化病对光动力疗法的临床反应,该方案似乎有前景且耐受良好。
研究设计与样本
- 干预性队列对照试验,第1组29例患者接受轻柔清创和15分钟氨基酮戊酸预孵育后蓝光照射(30分钟;20 J/cm2)。
- 第2组29例患者在清创和光动力疗法前口服维生素D3(每日10,000 IU,持续5或14天)。
- 基线时评估病灶计数和血清25-羟基维生素D3水平,并在3至6个月时评估病灶清除情况。
主要发现
- 第1组中,维生素D3缺乏患者(25-羟基维生素D3水平<31 ng/dL)的面部光线性角化病平均清除率为40.9%±42%,低于25-羟基维生素D3水平正常患者的62.6%±14.2%。
- 第2组高剂量维生素D3补充后总体光线性角化病病灶反应为72.5%±13.6%,显著高于第1组的54.4%±22.8%。
- 两组副作用无差异。
局限性
- 非随机试验设计(干预性队列与登记库来源的对照相匹配)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In mouse models of skin cancer, high-dose oral vitamin D3 (VD3; cholecalciferol) combined with photodynamic therapy (PDT) can improve the clearance of squamous precancers (actinic keratoses [AKs]). OBJECTIVE: To determine whether oral VD3 can improve the clinical efficacy of a painless PDT regimen in humans with AK. METHODS: The baseline lesion counts and serum 25-hydroxyvitamin D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months. RESULTS: In group 1, the mean clearance rates of facial AK were lower in patients with VD3 deficiency (25-hydroxyvitamin D3 level < 31 ng/dL; clearance rate, 40.9% ± 42%) than in patients with normal 25-hydroxyvitamin D3 levels (62.6% ± 14.2%). High-dose VD3 supplementation (group 2) significantly improved the overall AK lesion response (72.5% ± 13.6%) compared with that in group 1 (54.4% ± 22.8%). No differences in side effects were noted. LIMITATIONS: Nonrandomized trial design (interventional cohort matched to registry-based controls). CONCLUSIONS: Oral VD3 pretreatment significantly improves AK clinical responses to PDT. The regimen appears promising and well tolerated.
引用
- Bullock TA, Negrey J, Hu B, et al. Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial. J Am Acad Dermatol. 2022. PMID: 35314199. doi:10.1016/j.jaad.2022.02.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。